by Brad Dunn | Jan 25, 2021
Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, discusses the impact a new treatment for Hodgkin lymphoma — brentuximab vedotin — will have on frontline practitioners. The ECHELON-1 study, which concluded in 2017, found a...
by Brad Dunn | Jan 20, 2021
Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, discusses the results of the ECHELON-1 study of brentuximab vedotin as a frontline treatment for late-stage Hodgkin lymphoma. The study, which concluded in 2017, found a significant...
by Brad Dunn | Jan 17, 2021
Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, gives an overview of the ECHELON-1 study of brentuximab vedotin as a frontline treatment for late-stage Hodgkin lymphoma. The trial finished in 2017. The primary objective of the...
by Brad Dunn | Jan 14, 2021
Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, gives an overview of Hodgkin lymphoma (HL). HL is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and...
by Peter Ciszewski | Oct 30, 2020
John Kuruvilla, MD, from the Princess Margaret Cancer Centre summarized the latest quality of life data from the Phase III KEYNOTE-204 Hodgkin lymphoma study comparing pembrolizumab to brentuximab vedontin. The study involved adults with relapsed or refractory...
